Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 20/20 | 0.63 |
| ▸ | F2 | P00734 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12340129 | 0.96 | F2R (0.65) | F2RF2 | |
| SCHEMBL12340133 | 0.95 | F2R (0.56) | F2RF2 | |
| SCHEMBL12340158 | 0.93 | F2R (0.65) | F2RF2 | |
| SCHEMBL13968276 | 0.91 | F2R (0.53) | F2RF2 | |
| SCHEMBL12340123 | 0.89 | F2R (0.55) | F2RF2 | |
| SCHEMBL12340155 | 0.89 | F2R (0.67) | F2RF2 | |
| SCHEMBL13945253 | 0.84 | F2R (0.74) | F2RF2 | |
| SCHEMBL12340177 | 0.84 | F2R (0.63) | F2RF2 | |
| Aminodiphenylmethane SCHEMBL4551156 | 0.84 | F2R (0.52) | F2RF2 | |
| SCHEMBL12340161 | 0.81 | F2R (0.56) | F2RF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240175086-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASES | GENENTECH INC (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2024059336-A1 | INHIBITION OF PROTEASE-ACTIVATED RECEPTOR 2 (PAR2) PATHWAY FOR TREATMENT AND PREVENTION OF LYMPHEDEMA | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023147555-A2 | METHODS OF TREATING PAIN | ENDOSOME THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240175086-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASES | FCER2, F2RL1, F2RL3 | F2R 5/4885F2 664/4885 |
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | WEE1, WASF2, IDO1 | F2R 2248/4885F2 475/4885 |
| US-20090012006-A1 | Par-2 Antagonists | F2RL1, F2R, F2RL3 | F2R 2/4885F2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.